Skip to main content
. 2012 May 21;30(19):2401–2407. doi: 10.1200/JCO.2011.39.9394

Fig 4.

Fig 4.

Immunoblotting analyses of matched pre- and postregorafenib GI stromal tumor biopsies from four patients demonstrate KIT inactivation, expressed as percentage of preregorafenib KIT activation remaining in the matched postregorafenib sample [(postregorafenib phospho-KIT/total-KIT) ÷ (preregorafenib phospho-KIT/total KIT)]. Genomic analyses demonstrated KIT activation loop imatinib- and sunitinib-resistance mutations (mut) in each biopsy (D820Y in three patients, N822K in one patient). Total phosphatidylinositol 3-kinase (PI3-K) stain is a well-validated loading control, which serves as an indicator of cellular protein content in each biopsy.